Human Serum Albumin Improves Arterial Dysfunction during Early Resuscitation in Mouse Endotoxic Model via Reduced Oxidative and Nitrosative Stresses

Human serum albumin (HSA) is used as a resuscitation fluid in sepsis. This study investigated the potential protective properties of HSA on vascular function in a mouse endotoxic model in terms of oxidative and nitrosative stresses. Swiss mice were treated with either lipopolysaccharide (LPS) (50 mg/kg i.p.) or vehicle. One and five hours later, mice were infused with HSA (4%, 10 ml/kg), normal saline (0.9% NaCl, 30 ml/kg), or no fluid. Six hours after treatment, vascular reactivity was assessed on aortae and small mesenteric arteries. Measurements of NO and superoxide anion (O$_2^-$) by spin trapping and nuclear factor (NF)-κB, inducible NO synthase (iNOS), and peroxynitrite by Western blotting and immunohistochemical studies were conducted. HSA partially prevented the reduction of blood pressure induced by LPS and completely prevented both vascular hyporeactivity to phenylephrine and myogenic tone as well as endothelial dysfunction induced by the endotoxin. This was associated with a decreased up-regulation of NF-κB, iNOS, and peroxynitrite in the vascular wall. LPS-induced tissue increases in both NO and O$_2^-$ production was decreased by HSA. These data demonstrate the protective effect of HSA treatment in experimental endotoxic shock by reducing the inflammatory process leading to oxidative and nitrosative stresses and vascular hyporeactivity. (Am J Pathol 2007, 171:1753–1761; DOI: 10.2353/ajpath.2007.070316)
evidence from meta-analysis and the recently published Saline versus Albumin Fluid Evaluation Study\textsuperscript{16} does not support a survival benefit of HSA compared to crystalloid solutions. Nevertheless, the Sepsis Occurrence in Acutely Ill Patients Study\textsuperscript{16} suggests that treatment with HSA reduces mortality and benefits survival in septic patients with hypoalbuminemia. Among the mechanisms explaining the protective effect of HSA, a modulation of cellular reduced glutathione as well as transsignification of inflammatory genes and apoptosis have been reported.\textsuperscript{13,17} To our knowledge, a possible protective effect of HSA treatment against vascular disturbances and up-regulation of both NO and superoxide anion (O$_2^-$) production after endotoxic shock have not been investigated. This study investigated the potential protective anti-inflammatory and anti-oxidant properties of HSA on vascular dysfunction in an endotoxic model induced by the bacterial lipopolysaccharide (LPS).

**Materials and Methods**

**Animals and Protocols: Experiments**

All experiments were in accordance with the ethical regulations approved by the regional ethics committee for animal experimentation “CREMEAS” (Strasbourg, France). Male Swiss mice (35 to 40 g) were used. LPS (from Escherichia coli 055:B5; Sigma Aldrich, Saint Quentin Falavier, France) was administered at a dose of 50 mg/kg i.p. Control mice received an equivalent volume of vehicle (0.9% NaCl solution) (sham group). One and five hours later, mice given LPS were randomized for intravenous resuscitation by using 10 ml/kg of 4% HSA (Viallevex; LFB, Paris, France), 30 ml/kg 0.9% saline, or no fluid resuscitation. Mean blood pressure and heart rate were recorded for 30 seconds every 15 minutes on a daily basis. Data were averaged for each mouse.

We measured serum albumin, chloride, and total CO$_2$ (as a surrogate of acid-base status) (Roche/Hitachi Modular P 800; Roche Diagnostics, Meylan, France) under basal conditions and after 6 hours of LPS in mice receiving either saline or HSA (n = 6 to 7 for each group of mice). LPS treatment did not significantly affect native albumin concentrations in the mouse groups (24 ± 0.9 g/L and 25 ± 0.8 g/L for control and LPS-treated mice, respectively). The plasma level of albumin was not modified by saline (25 ± 1.1 g/L). Although, the colorimetric quantitative determination of serum albumin did not allow differentiation between murine albumin and HSA, levels of total serum albumin were significantly enhanced after HSA treatment (32 ± 0.6 g/L). Furthermore, neither LPS treatment nor saline resuscitation affected plasma chloride levels (indirect potentiometry) (104 ± 0.6 mmol/L in control mice, 110 ± 0.5 mmol/L in LPS-treated mice, 102 ± 1.6 mmol/L in HSA treated mice, and 108 ± 1 mmol/L in saline resuscitation mice). Thus, the load of saline in the control group did not induce hyperchloremia under the experimental conditions used. As expected, LPS treatment reduced total CO$_2$ level (23 ± 0.4 control mice versus 19 ± 0.7 mmol/L LPS-treated mice, *P < 0.05), as measured by enzymatic method. Such a reduction was not observed after either saline or HSA, being 21 ± 0.4 mmol/L and 22 ± 0.8 mmol/L, respectively.

**Continuous Measurements of Blood Pressure and Heart Rate by Telemetry**

Mean blood pressure and heart rate were recorded using telemetry (Data Sciences, St. Paul, MN). This system consists of implantable radio frequency transmitters (TA11-PA20, 3.4 g) and a receiver placed under the holding cage of each animal. For the surgical procedure, mice were anesthetized with ketamine (100 mg/kg, i.p.) mixed with medetomidine (50 µg/kg, i.p.). The left carotid artery was isolated, the catheter linked to the transmitter was inserted into the carotid artery, and sutures were tied around the catheter and the artery. The body of the transmitter was placed into a subcutaneous pocket along the animal’s right flank. The skin incisions were then closed. Animals were kept under warming lights until they recovered. Animals were returned to their cages and allowed to recover from the surgery for 1 week. For data acquisition and analysis, mean blood pressure and heart rate were recorded for 30 seconds every 15 minutes on a daily basis. Data were averaged for each mouse.

**Vascular Reactivity**

**Aortic Rings**

Vascular reactivity of aortic rings was studied on a wire myograph (EMKA Technologies, Paris, France). The experiments were performed at 37°C in a physiological salt solution with the following composition: 119 mmol/L NaCl, 4.7 mmol/L KCl, 14.9 mmol/L NaHCO$_3$, 1.2 mmol/L MgSO$_4$, 7H$_2$O, 2.5 mmol/L CaCl$_2$, 1.18 mmol/L KH$_2$PO$_4$, and 5.5 mmol/L glucose, continuously bubbled with 95% O$_2$ and 5% CO$_2$. After an equilibration period (at least 20 minutes) under the optimal passive tension, two successive contractions in response to the combination of KCl depolarization (100 mmol/L) and 10 µmol/L phenylephrine (Pe) (Sigma-Aldrich, Saint Quentin Falavier, France) were used to test the maximal contractile capacity of the vessels. After washing, endothelial function was assessed by testing the relaxing effect of acetylcholine (Ach 1 µmol/L) after precontraction by 1 µmol/L Pe. After a 20-minute washout period, concentration-response curves to Pe were elicited by cumulative administration of the vasoconstrictor agonist (1 mmol/L to 100 µmol/L) to vessels with endothelium in presence or absence of the NO-synthase inhibitor, N$^\text{G}$-nitroarginine-methyl-ester (L-NAME, 100 µmol/L; Sigma-Aldrich). The inhibi-
itor was added in the bath 30 minutes before the addition of Pe.

**Isolated Mesenteric Arteries**

We assessed myogenic tone in SMAs (~130 to 160 μm diameter). Mesenteric arteries were cannulated at both ends in a video-monitored perfusion system (Living Systems Instrumentation, Burlington, VT). Arteries were bathed in physiological salt solution (pH 7.4; PO2, 160 mm Hg; PCO2, 37 mm Hg). Pressure was controlled by a servo-perfusion system, and flow was generated by a peristaltic pump. Initially, diameter changes were measured by increasing the luminal pressure from 10 to 125 mmHg.

The presence of a functional endothelium was assessed by applying 10 μmol/L Ach in arteries precontracted with 1 μmol/L U46619. At the end of each experiment, to determine the passive diameter of the artery and to evaluate myogenic tone, arteries were perfused and superfused with a Ca2+ -free physiological salt solution containing 2 mmol/L EGTA and 10 μmol/L sodium nitroprusside and pressure steps repeated. Myogenic tone was calculated at each pressure as follows: myogenic tone = passive diameter minus active diameter. In another set of experiments, the same protocol was used in the presence of 100 μmol/L L-NAME.

**Staining and Imaging by Confocal Microscopy**

Vessels were frozen and cut into 10-μm sections. Fixed sections were incubated (2 hours at room temperature) in a blocking buffer (5% nonfat dry milk in phosphate-buffered saline) and then incubated overnight (4°C) with a monoclonal mouse anti-iNOS antibody (1:50; Transduction Laboratories, Heidelberg, Germany) for iNOS immunostaining. A polyclonal NF-B p65 antibody was added in the bath 30 minutes before the addition of Pe.

**Western Blotting**

Lung tissue samples were crushed and homogenized and ~50 μg of total protein from the supernatant fraction was loaded onto 8% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Blots were probed with a monoclonal mouse anti-iNOS (Transduction Laboratories). Proteins were transferred to nitrocellulose membranes and probed with a monoclonal mouse anti-α-actin antibody (Sigma-Aldrich). Bound antibodies were detected with a secondary peroxidase-conjugated antimouse IgG (Promega, Madison, WI). The blots were visualized using an enhanced chemiluminescence system (ECL Plus; Amersham, Buckinghamshire, UK).

**Electronic Paramagnetic Resonance (EPR) Studies**

**NO Spin Trapping**

After 5.5 hours, N,N-diethyldithiocarbamate (DETC) and Fe2+-citrate complex were separately injected into mice at the following doses: 400 mg/kg DETC (intraperitoneally) and 40 mg/kg FeSO4·7H2O in a solution containing 200 mg/kg of sodium citrate (s.c.). The animals were anesthetized and sacrificed 30 minutes later. Tissues (aorta, heart, and lung) and blood samples were harvested and flash-frozen in liquid nitrogen for subsequent EPR assay. These studies were performed on a tabletop x-band spectrometer miniscope (MS200; Magnettech, Berlin, Germany). Recordings were made at 77°K using a Dewar flask. The instrument settings were 10 mW of microwave power, 1 mT of amplitude modulation, 100 kHz of modulation frequency, 60 seconds of sweep time, and 5 numbers of scans.18 Levels of NO were expressed as amplitude of signal in unit per weight of dried sample.

**Superoxide Anion Spin Trapping**

Mice were sacrificed, and selected organs were dissected and placed in cold buffer. Freshly isolated samples were allowed to equilibrate in deferoxamine-related Krebs-HEPES solution containing 500 μmol/L L-1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrroldin (CMH), 25 μmol/L deferoxamine, and 5 μmol/L DETC at 37°C for 60 minutes. The reaction was stopped by placing samples on ice and then freezing in liquid nitrogen and analyzing in a Dewar flask by EPR spectroscopy. The instrument settings were as follows: temperature, 77°K; microwave power, 1 mW; amplitude modulation, 0.5 mT; sweep time, 60 seconds; field sweep, 60 G.

**Data Analysis**

Data obtained during measurements of arterial pressure and heart rate were compared using a nonparametric Wilcoxon signed rank test. Two-way analysis of variance for repeated measurements was used for comparison of vascular reactivity (data were tested for homogeneity of variance by Levene’s statistics), and nonparametric Kruskal-Wallis test or Mann-Whitney test were used for comparison Western blotting, NO, superoxide, and immunostaining signal measurements between the four groups. When a significant difference was found between groups, subsequent
post hoc tests were performed. All these tests were performed with the Statview version 5.0 software (SAS Institute, Cary, NC). *P < 0.05 was considered statistically significant. The effects of Ach were quantified as the percentage of relaxation in preparations previously contracted with Pe. All values are presented as mean ± SEM for n experiments. n represents the number of animals.

Results

Mean Arterial Pressure and Heart Rate in Mice

The MAP (Figure 1A) and heart rate were similar in all mouse groups before experimentation. In the sham group, MAP remained stable during the 6 hours of measurement. LPS treatment induced a significant decrease in MAP (P < 0.05). After LPS injection, saline and HSA partially reversed MAP to similar extents (P < 0.05) but remained low compared to the MAP of sham group. Compared to sham (431 ± 9 beats/minute), LPS raised heart rate (492 ± 11 beats/minute) (P < 0.05, n = 6 to 7). Saline and HSA did not alter heart rate (476 ± 10 and 481 ± 12 beats/minute).

HSA Prevents Vascular Hyporeactivity and Improves Endothelial Dysfunction Induced by LPS

Aortae

Pe produced a concentration-dependent increase in contraction of intact aortic rings (Figure 2A). Compared to the sham group, the vascular responses to Pe were significantly decreased in aortae from LPS-treated mice (P < 0.01). Hence, LPS-induced hyporeactivity was not modified in the aorta harvested from animals resuscitated with saline (P < 0.01). Conversely, HSA prevented the vascular hyporeactivity elicited by LPS. Concerning endothelial function, Ach produced relaxation in a concentration-dependent manner (Figure 2B). Ach response was significantly reduced after LPS treatment (P < 0.05). Interestingly, HSA, but not saline resuscitation, improved relaxation to Ach (P < 0.05).

SMAs

Compared to the sham group (70 ± 11 μm, n = 8), the contractile response, expressed as reduction of vessel diameter, to KCl depolarization was significantly decreased in SMAs taken from LPS-treated mice (29 ± 6 μm, n = 7) (P < 0.01). HSA (49 ± 9 μm, n = 8) but not saline (32 ± 7 μm, n = 6) partially prevented the hyporeactivity to KCl depolarization to the level of sham group (P < 0.01).

Compared to SMAs from the sham group, the contractile response to Pe was significantly decreased in SMAs from LPS-treated mice alone or after saline (31 ± 5 μm and 44 ± 6 μm versus 106 ± 13 μm) (P < 0.01). After HSA treatment, the hyporeactivity induced by LPS was partially prevented, and the contractile response was not significantly different to the sham group (70 ± 11 μm, n =
8). Myogenic tone, which was normalized to the corresponding passive arterial diameter, was significantly decreased in mice treated with LPS \((P < 0.01, \text{compared to sham})\). Most importantly, HSA but not saline resuscitation prevented the reduction of myogenic tone induced by LPS treatment (Figure 2C).

The Protective Effect of HSA on LPS-Induced Hyporeactivity Is Blunted by L-NAME

To investigate the mechanisms involved in the vascular hyporeactivity induced by LPS, the role of NO was evaluated by examining the effects of L-NAME on Pe-induced contractions. In the sham group, L-NAME did not modify either contraction to Pe (aorta) or myogenic tone (SMAs) (Figure 3, A and B). However, L-NAME abolished the LPS-induced hyporeactivity to Pe \((P < 0.01)\) and myogenic tone \((P < 0.01)\).

HSA Prevents LPS-Dependent NO Overproduction and iNOS Expression in the Aorta

Compared to the sham group, LPS induced marked increase in NO production in the sham group \((P < 0.05)\). HSA but not saline resuscitation prevented LPS-induced NO overproduction \((P < 0.05)\) (Figure 3C). In agreement with these data, weak or no staining of iNOS was found in aortae from sham group (D), no fluid resuscitation group (E), and HSA group mice (F). Green fluorescence was linked to secondary Alexa 488 anti-mouse-conjugated antibody. Scale bars = 150 μm.
by HSA treatment (personal observations). The negative control obtained by incubation with a secondary murine fluorescent-labeled antibody did not display any staining (not shown).

**HSA Prevents Tissue LPS-Induced NO Overproduction and Increase in iNOS Expression**

Compared to the sham group, LPS induced significant increases in NO production as detected by the NO-Fe(DeTC)₂ EPR signal in the heart \((P < 0.05)\) and lungs \((P < 0.05)\) (Figure 4, A and B). Saline did not alter LPS-induced NO production. Conversely, HSA resuscitation reduced the increases in LPS-induced NO production in both tissues \((P < 0.05)\). Western blot analysis confirmed a decrease in iNOS expression in the lungs of HAS-treated animals (Figure 4C).

**HSA Reduced the LPS-Induced Up-Regulation of NF-κB**

The NF-κB heterodimer is co-localized in the cytoplasm with the inhibitory protein IκB. On cell stimulation, IκB is phosphorylated, removed, and degraded, allowing NF-κB to induce transcription. Immunohistochemical staining of the p65 subunit of NF-κB was used as an index of activation of NF-κB (Figure 5). No specific staining occurred in aortae from the sham group (4.2 ± 1.5 arbitrary units) (Figure 5A). Treatment with LPS induced marked staining of the p65/RelA subunit of NF-κB in the medial and adventitial layers of the aorta (19.4 ± 3.1 arbitrary units, \(P < 0.05\)) (Figure 5B). This staining was almost abolished in aortic rings taken from LPS-treated mice receiving HSA (8 ± 1 arbitrary units) (Figure 5C). Negative controls obtained by incubation with the secondary rabbit fluorescence-labeled antibody did not display any staining (not shown).
control obtained by incubation with the secondary murine fluorescent-labeled antibody did not display any staining (not shown).

Discussion

In this study, we provide evidence for a protective role of HSA on vascular function during LPS-induced shock. HSA improves LPS-induced endothelial dysfunction and reduces LPS-induced vascular hyporeactivity. This effect was associated with a reduced iNOS expression in the vascular wall as well as reduced NO production in aorta and organs such as lung and heart. Moreover, HSA reduced in situ activation of the transcriptional factor NF-κB, thus reducing oxidative and nitrosative stresses in aorta, heart, and lung.

Prompt restoration of intravascular volume is an early goal in the treatment of patients with septic shock, and although the use of crystalloids or colloids for volume replacement in critically ill patients is still debated, both fluids are widely used, and both reduce mortality to the same extent. In our study, mice did not receive echolamines. Nevertheless, we found that early volume replacement with either HSA or saline solution yielded similar hemodynamic improvements in MAP after LPS treatment although both solutions possess different volumic expanding properties.

Other studies have already suggested a beneficial role of HSA in sepsis-induced organ dysfunction, but the mechanism remains unclear, especially with respect to cardiovascular aspects. Thus, HSA has been reported to improve heart function in endotoxic shock in rat in which HSA, but not other resuscitation fluids, reduced iNOS mRNA transcription and subsequent expression of the enzyme in cardiomyocytes. These results suggest a role for HSA in the reduction of sepsis-induced cardiac failure.

A major finding of our work was that HSA, but not saline, improved endothelial dysfunction and prevented the vascular hyporeactivity to Pe (aorta) and myogenic tone (resistance arteries). To our knowledge, this is the first report to shed new light on the beneficial effect of HSA treatment on vascular dysfunction induced by LPS. This property of HSA probably plays a major role in controlling the process of refractory vasoplegia in patients with septic shock. It is well documented, including in human arteries, that the vascular hyporeactivity to different vasoconstrictors after LPS administration is linked with overproduction of NO because of iNOS activation within the vascular wall. Prompt restoration of intravascular volume is an early goal in the treatment of patients with septic shock, and although the use of crystalloids or colloids for volume replacement in critically ill patients is still debated, both fluids are widely used, and both reduce mortality to the same extent. In our study, mice did not receive echolamines. Nevertheless, we found that early volume replacement with either HSA or saline solution yielded similar hemodynamic improvements in MAP after LPS treatment although both solutions possess different volumic expanding properties.

Other studies have already suggested a beneficial role of HSA in sepsis-induced organ dysfunction, but the mechanism remains unclear, especially with respect to cardiovascular aspects. Thus, HSA has been reported to improve heart function in endotoxic shock in rat in which HSA, but not other resuscitation fluids, reduced iNOS mRNA transcription and subsequent expression of the enzyme in cardiomyocytes. These results suggest a role for HSA in the reduction of sepsis-induced cardiac failure.

A major finding of our work was that HSA, but not saline, improved endothelial dysfunction and prevented the vascular hyporeactivity to Pe (aorta) and myogenic tone (resistance arteries). To our knowledge, this is the first report to shed new light on the beneficial effect of HSA treatment on vascular dysfunction induced by LPS. This property of HSA probably plays a major role in controlling the process of refractory vasoplegia in patients with septic shock. It is well documented, including in human arteries, that the vascular hyporeactivity to different vasoconstrictors after LPS administration is linked with overproduction of NO because of iNOS activation within the vascular wall. Prompt restoration of intravascular volume is an early goal in the treatment of patients with septic shock, and although the use of crystalloids or colloids for volume replacement in critically ill patients is still debated, both fluids are widely used, and both reduce mortality to the same extent. In our study, mice did not receive echolamines. Nevertheless, we found that early volume replacement with either HSA or saline solution yielded similar hemodynamic improvements in MAP after LPS treatment although both solutions possess different volumic expanding properties. Other studies have already suggested a beneficial role of HSA in sepsis-induced organ dysfunction, but the mechanism remains unclear, especially with respect to cardiovascular aspects. Thus, HSA has been reported to improve heart function in endotoxic shock in rat in which HSA, but not other resuscitation fluids, reduced iNOS mRNA transcription and subsequent expression of the enzyme in cardiomyocytes. These results suggest a role for HSA in the reduction of sepsis-induced cardiac failure.

A major finding of our work was that HSA, but not saline, improved endothelial dysfunction and prevented the vascular hyporeactivity to Pe (aorta) and myogenic tone (resistance arteries). To our knowledge, this is the first report to shed new light on the beneficial effect of HSA treatment on vascular dysfunction induced by LPS. This property of HSA probably plays a major role in controlling the process of refractory vasoplegia in patients with septic shock. It is well documented, including in human arteries, that the vascular hyporeactivity to different vasoconstrictors after LPS administration is linked with overproduction of NO because of iNOS activation within the vascular wall. Prompt restoration of intravascular volume is an early goal in the treatment of patients with septic shock, and although the use of crystalloids or colloids for volume replacement in critically ill patients is still debated, both fluids are widely used, and both reduce mortality to the same extent. In our study, mice did not receive echolamines. Nevertheless, we found that early volume replacement with either HSA or saline solution yielded similar hemodynamic improvements in MAP after LPS treatment although both solutions possess different volumic expanding properties. Other studies have already suggested a beneficial role of HSA in sepsis-induced organ dysfunction, but the mechanism remains unclear, especially with respect to cardiovascular aspects. Thus, HSA has been reported to improve heart function in endotoxic shock in rat in which HSA, but not other resuscitation fluids, reduced iNOS mRNA transcription and subsequent expression of the enzyme in cardiomyocytes. These results suggest a role for HSA in the reduction of sepsis-induced cardiac failure.
SMAs. Furthermore, HSA, but not saline, prevented the ability of LPS to increase NO production and iNOS expression in the aorta. Moreover, HSA prevented the overproduction of NO and iNOS expression in target organs such as the heart and the lung. Altogether, we demonstrate that HSA overcomes the deleterious effect of an overproduction of NO that is associated with an induction of iNOS in vascular and target organs after LPS treatment without any deleterious effect of the use of nonselective NOS inhibitor such as pulmonary hypertension associated with concomitant endothelial NO synthase blockade. In contrast, we found that HSA tended to prevent LPS-induced endothelial dysfunction. The latter is linked to reduced endothelial NO release in the aorta. Sepsis is also associated with increased oxidative stress, marked by increased circulating and tissue $O_2^-$ production. It is possible that the beneficial effects of HSA are probably linked to its anti-oxidant properties, probably because of its ability either to scavenge free radicals as suggested by Quinlan and colleagues or to interact with circulating molecules or cells such as polymorphonuclear cells involved in the process leading to enhanced reactive oxygen species production. Moreover, HSA might also have a direct beneficial effect on the vascular wall, endothelium, and glycoalyx. Indeed, HSA can bind with gp60 cell membrane receptors, allowing its internalization and alteration of biochemical intracellular pathways leading to oxidative stress. Thus, it is likely that the antioxidant properties of HSA is potentially able to reduce circulating and tissue $O_2^-$ production and thus prevent the endothelial dysfunction and vascular hyporeactivity. Indeed, the reduction of $O_2^-$ production leads to a decrease in its interaction with NO and thus in the production of the highly toxic ONOO$^-$. Peroxynitrite is produced in large amounts during septic shock and has harmful effects on various tissues, especially in blood vessels as reported by Szabo and colleagues. Furthermore, $O_2^-$ is involved in leukocyte infiltration, induces DNA damage, worsens lipid peroxidation, and promotes the synthesis of proinflammatory cytokines. The mechanism whereby HSA decreases oxidative stress has not been assessed previously, but in this study we demonstrate that HSA, but not saline, prevents the increases in $O_2^-$ production in aorta and end target organs such as heart and lung. Moreover, HSA also attenuated LPS-induced ONOO$^-$ production in the aortic wall. This property of HSA is essential in preventing vascular hyporeactivity, endothelial dysfunction, and end organ damage in endotoxic animals and probably in septic shock patients.

Finally, the mechanism whereby LPS induces shock is associated with its ability to activate the NF-$\kappa$B/Rel transcription family, enabling the expression of several critical genes involved in the pathogenesis of septic shock. We report that HSA reduces NF-$\kappa$B activation in the vascular wall, which in turn will reduce oxidative and nitrosative stresses induced by LPS in blood vessels and so prevents vascular hyporeactivity while also improving endothelial dysfunction, as reported in this study.

Our study was designed to better understand the mechanisms of the protective effects of HSA on vascular dysfunction during endotoxemia. The model that we used reproduced hemodynamics of septic patients, and HSA was infused early in this mouse endotoxic shock model. Thus, it can be speculated that the anti-inflammatory and anti-oxidant effects of HSA were not overwhelmed, and the results from a more aggressive LPS challenge or a delayed HSA infusion may have been different. Such considerations may explain some discrepancies with data reported in human clinical trials. In conclusion, our study demonstrates a protective effect of HSA treatment in endotoxic shock, a condition that is associated with inflammatory processes that lead to oxidative and nitrosative stresses and vascular hyporeactivity in animal models. Our data provide a rationale for HSA treatment in patients with septic shock.

Acknowledgments

We thank Dr. Gallois for help in quantitative determination of mouse serum albumin, chloride, and total CO$_2$; and Prof. Ismael Lohier for a careful reading of the manuscript.

References


